Anne S. Renteria - Concepedia

Author

Anne S. Renteria

Icahn School of Medicine at Mount Sinai ORCID

Also Known As

A Renteria, A S Renteria, A. S. Renteria, Anne Renteria, Anne S Renteria, Anne S. Renteria, Anne S. S. Renteria, Anne Sigrid Renteria, S Kim, Wilkins, Olivia

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Icahn School of Medicine at Mount Sinai Universität Hamburg University of Regensburg Massachusetts General Hospital Chulalongkorn University

About

Anne S. Renteria is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	91
2	Public Health	2	2	32
3	Blood Transplantation	1	1	45
4	Cellular Therapies	1	1	45
5	Epidemiology	1	1	16

Anne S. Renteria

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium Andrew C. Harris, Rachel Young, Steven M. Devine, Biology of Blood and Marrow Transplantation	2015	882
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival Matthew J. Hartwell, Umut Özbek, Ernst Holler, JCI Insight	2017	218
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD Hannah Major-Monfried, Anne S. Renteria, Attaphol Pawarode, Blood	2018	202
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors Shernan G. Holtan, Nandita Khera, John E. Levine, Blood	2016	58
Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Yi‐Bin Chen, Nirav N. Shah, Anne S. Renteria, Blood Advances Cell TherapyGraft-versus-host DiseaseTransplantationMarrow TransplantationAutoimmune Disease	2019	45
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802 Shernan G. Holtan, Todd E. DeFor, Angela Panoskaltsis‐Mortari, Blood Advances	2018	42
A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease Yngvar Fløisand, Mark A. Schroeder, Patrice Chevallier, Bone Marrow Transplantation	2021	17
Where you live can impact your cancer risk: a look at multiple myeloma in New York City Geetanjali R. Kamath, Anne S. Renteria, Sundar Jagannath, Annals of Epidemiology EpidemiologyCancer RiskCancer EpidemiologyMedicineEpidemiology Of Cancer	2020	16
Multiple myeloma, race, insurance and treatment Himanshu Joshi, Sylvia Lin, Kezhen Fei, Cancer Epidemiology Hematological MalignancyOncologyHealth PolicyHematologyHealth Insurance	2021	16
Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma Sara Kim, Anne S. Renteria, Amir Steinberg, Cytotherapy Hematological MalignancyUp-front UseOncologyPharmacoeconomic ImpactStem Cells	2014	14

Page 1